BIOGEN INC. Inventory, Finished Goods, Net of Reserves
BIOGEN INC. (BIIB) had Inventory, Finished Goods, Net of Reserves of $458.20 million as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-04-29
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $458.20M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $424.90M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $440.50M.
- 2025-06-30: Inventory, Finished Goods, Net of Reserves $478.00M.
| Period end | Inventory, Finished Goods, Net of Reserves | Inventory, Finished Goods, Net of Reserves as first filed |
|---|---|---|
| 2026-03-31 | $458.20M 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $424.90M 10-Q · filed 2026-04-29 | |
| 2025-09-30 | $440.50M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $478.00M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $367.90M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $353.80M 10-K · filed 2026-02-06 | |
| 2024-09-30 | $391.00M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $395.00M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $347.90M 10-Q · filed 2024-04-24 | |
| 2023-12-31 | $255.40M 10-K · filed 2025-02-12 | |
| 2023-09-30 | $316.10M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $194.80M 10-Q · filed 2023-07-25 | |
| 2023-03-31 | $205.90M 10-Q · filed 2023-04-25 | |
| 2022-12-31 | $200.40M 10-K · filed 2024-02-14 | |
| 2022-09-30 | $209.80M 10-Q · filed 2022-10-25 | |
| 2022-06-30 | $209.90M 10-Q · filed 2022-07-20 | |
| 2022-03-31 | $205.30M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $187.90M 10-K · filed 2023-02-15 | |
| 2021-09-30 | $201.10M 10-Q · filed 2021-10-20 | |
| 2021-06-30 | $203.80M 10-Q · filed 2021-07-22 | |
| 2021-03-31 | $205.70M 10-Q · filed 2021-04-22 | |
| 2020-12-31 | $209.20M 10-K · filed 2022-02-03 | |
| 2020-09-30 | $199.40M 10-Q · filed 2020-10-21 | |
| 2020-06-30 | $198.90M 10-Q · filed 2020-07-22 | |
| 2020-03-31 | $172.70M 10-Q · filed 2020-04-23 | |
| 2019-12-31 | $174.50M 10-K · filed 2021-02-03 | |
| 2019-09-30 | $170.80M 10-Q · filed 2019-10-22 | |
| 2019-06-30 | $144.10M 10-Q · filed 2019-07-24 | |
| 2019-03-31 | $108.20M 10-Q · filed 2019-04-24 | |
| 2018-12-31 | $133.50M 10-K · filed 2020-02-06 | |
| 2018-09-30 | $136.50M 10-Q · filed 2018-10-23 | |
| 2018-06-30 | $158.50M 10-Q · filed 2018-07-24 | |
| 2018-03-31 | $148.00M 10-Q · filed 2018-04-24 | |
| 2017-12-31 | $157.40M 10-K · filed 2019-02-06 | |
| 2017-09-30 | $175.50M 10-Q · filed 2017-10-24 | |
| 2017-06-30 | $184.20M 10-Q · filed 2017-07-25 | |
| 2017-03-31 | $156.80M 10-Q · filed 2017-04-25 | |
| 2016-12-31 | $170.30M 10-K · filed 2018-02-01 | |
| 2016-09-30 | $171.10M 10-Q · filed 2016-10-26 | |
| 2016-06-30 | $139.10M 10-Q · filed 2016-07-21 | |
| 2016-03-31 | $144.10M 10-Q · filed 2016-04-21 | |
| 2015-12-31 | $143.00M 10-K · filed 2017-02-02 | |
| 2015-09-30 | $159.70M 10-Q · filed 2015-10-21 | |
| 2015-06-30 | $175.80M 10-Q · filed 2015-07-24 | |
| 2015-03-31 | $172.60M 10-Q · filed 2015-04-24 | |
| 2014-12-31 | $164.20M 10-K · filed 2016-02-03 | |
| 2014-09-30 | $140.70M 10-Q · filed 2014-10-22 | |
| 2014-06-30 | $143.70M 10-Q · filed 2014-07-23 | |
| 2014-03-31 | $128.90M 10-Q · filed 2014-04-23 | |
| 2013-12-31 | $108.60M 10-K · filed 2015-02-04 | |
| 2013-09-30 | $112.50M 10-Q · filed 2013-10-28 | |
| 2013-06-30 | $113.10M 10-Q · filed 2013-07-25 | |
| 2012-12-31 | $100.70M 10-K · filed 2014-02-06 | $115.10M 10-Q · filed 2013-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |